{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:28:37Z","timestamp":1781108917219,"version":"3.54.1"},"reference-count":359,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018707","name":"European Commission Reforming and enhancing the European Research and Innovation system","doi-asserted-by":"publisher","award":["101071485"],"award-info":[{"award-number":["101071485"]}],"id":[{"id":"10.13039\/100018707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.biopha.2025.118388","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T01:06:48Z","timestamp":1754356008000},"page":"118388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting the root cause of obesity-related comorbidities through weight independent and dependent actions on insulin sensitivity: Benefits of dual amylin and calcitonin receptor agonists"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-4319","authenticated-orcid":false,"given":"Anna Thors\u00f8","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Anna","family":"Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled Elhady","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie Ahmt","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Benmarce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118388_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1226655","article-title":"Insulin signaling and its application","author":"Le","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118388_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142241","article-title":"Insulin signaling in health and disease","author":"Saltiel","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2025.118388_bib3","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmet.2021.03.020","article-title":"The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia","author":"Sylow","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118388_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155607","article-title":"Hepatic insulin receptor: new views on the mechanisms of liver disease","author":"Lee","year":"2023","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.biopha.2025.118388_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cmet.2021.03.019","article-title":"Insulin action in adipocytes, adipose remodeling, and systemic effects","author":"Santoro","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118388_bib6","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1172\/JCI29189","article-title":"Insulin resistance and pancreatic \u03b2 cell failure","author":"Kasuga","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2025.118388_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","article-title":"The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes","author":"Kahn","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2025.118388_bib8","doi-asserted-by":"crossref","DOI":"10.2337\/dc09-S302","article-title":"Skeletal muscle insulin resistance is the primary defect in type 2 diabetes","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.biopha.2025.118388_bib9","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s00125-013-2995-9","article-title":"Insulin-mediated suppression of lipolysis in adipose tissue and skeletal muscle of obese type 2 diabetic men and men with normal glucose tolerance","volume":"56","author":"Jocken","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2025.118388_bib10","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.2337\/db11-0425","article-title":"Fatty acids, obesity, and insulin resistance: time for a reevaluation","author":"Karpe","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2025.118388_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrendo.2017.80","article-title":"Regulation of hepatic glucose metabolism in health and disease","author":"Petersen","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"31","key":"10.1016\/j.biopha.2025.118388_bib13","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"Cmaj"},{"key":"10.1016\/j.biopha.2025.118388_bib14","first-page":"2537","article-title":"Change in overweight from childhood to early adulthood and risk of type 2 diabetes","author":"Bjerregaard","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/clinem\/dgz261","article-title":"Postprandial dyslipidemia, hyperinsulinemia, and impaired gut Peptides\/Bile acids in adolescents with obesity","volume":"105","author":"Higgins","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"25","key":"10.1016\/j.biopha.2025.118388_bib16","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1056\/NEJMoa1503840","article-title":"Body-Mass index in 2.3 million adolescents and cardiovascular death in adulthood","volume":"374","author":"Twig","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118388_bib17","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: definition and subtypes","author":"Han","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118388_bib18","article-title":"The crucial role and mechanism of insulin resistance in metabolic disease","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118388_bib19","article-title":"Factors affecting obesity and its treatment","volume":"16","author":"Singh","year":"2019","journal-title":"Obes. Med."},{"issue":"February","key":"10.1016\/j.biopha.2025.118388_bib20","article-title":"Adipose tissue and insulin resistance in obese","volume":"137","author":"Ahmed","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/joim.12540","article-title":"Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids","volume":"280","author":"Smith","year":"2016","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000324","article-title":"Hypertrophy and\/or hyperplasia: dynamics of adipose tissue growth","volume":"5","author":"Jo","year":"2009","journal-title":"PLoS Comput. Biol."},{"issue":"S1","key":"10.1016\/j.biopha.2025.118388_bib23","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH \u2013 role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tem.2015.01.006","article-title":"Insulin resistance and impaired adipogenesis","volume":"26","author":"Gustafson","year":"2015","journal-title":"Trends Endocrinol. Metab. TEM"},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib25","doi-asserted-by":"crossref","first-page":"R284","DOI":"10.1152\/ajpregu.00257.2017","article-title":"Adipose cell size: importance in health and disease","volume":"315","author":"Stenkula","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.biopha.2025.118388_bib26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3389\/fimmu.2019.01173","article-title":"Adipose tissue-resident immune cells in obesity and type 2 diabetes","volume":"10","author":"Lu","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0148607108325251","article-title":"Adipose inflammation, insulin resistance, and cardiovascular disease","volume":"32","author":"Shah","year":"2008","journal-title":"Jpen. J. Parenter. Enter. Nutr."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/13813450802181047","article-title":"Insulin resistance associated to obesity: the link TNF-alpha","volume":"114","author":"Nieto-Vazquez","year":"2008","journal-title":"Arch. Physiol. Biochem."},{"issue":"S2","key":"10.1016\/j.biopha.2025.118388_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1467-789X.2012.01035.x","article-title":"Visceral fat and metabolic inflammation: the portal theory revisited","volume":"13","author":"Item","year":"2012","journal-title":"Obes. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib30","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.drudis.2021.11.001","article-title":"Obesity and insulin resistance: pathophysiology and treatment","volume":"27","author":"Tong","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118388_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bjd.12208","article-title":"The role of mitochondrial function and cellular bioenergetics in ageing and disease","volume":"169","author":"Brand","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib32","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa017","article-title":"Mitochondrial dysfunction, insulin resistance, and potential genetic implications","volume":"161","author":"Sangwung","year":"2020","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2025.118388_bib33","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbadis.2016.11.010","article-title":"Mitochondrial dysfunction and oxidative stress in metabolic disorders \u2014 a step towards mitochondria based therapeutic strategies","author":"Bhatti","year":"2017","journal-title":"Biochim. Et. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.biopha.2025.118388_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/CIRCRESAHA.107.165472","article-title":"Role of mitochondrial dysfunction in insulin resistance","author":"Kim","year":"2008","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/db11-1652","article-title":"Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver","volume":"62","author":"Otoda","year":"2013","journal-title":"Diabetes"},{"issue":"March","key":"10.1016\/j.biopha.2025.118388_bib36","article-title":"The crucial role and mechanism of insulin resistance in metabolic disease","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"July","key":"10.1016\/j.biopha.2025.118388_bib37","first-page":"1","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"June","key":"10.1016\/j.biopha.2025.118388_bib38","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: standards of care in Diabetes\u20142023","volume":"46","author":"Elsayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.118388_bib39","article-title":"Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue","author":"da Silva Rosa","year":"2020","journal-title":"Physiol. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib40","article-title":"Defining and characterizing the progression of type 2 diabetes","volume":"32","author":"Fonseca","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4239\/wjd.v6.i1.109","article-title":"\u03b2-cell dysfunction: its critical role in prevention and management of type 2 diabetes","volume":"6","author":"Saisho","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.biopha.2025.118388_bib42","article-title":"Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus","volume":"85","author":"Shah","year":"2000"},{"key":"10.1016\/j.biopha.2025.118388_bib43","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118388_bib44","doi-asserted-by":"crossref","unstructured":"Diuneen, S., Alzaid, A., Turk, D., Rizza, R., 1995. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM.","DOI":"10.1007\/s001250050290"},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1467-789X.2008.00544.x","article-title":"Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle","volume":"10","author":"Corpeleijn","year":"2009","journal-title":"Obes. Rev. Off. J. Int. Assoc. Study Obes."},{"key":"10.1016\/j.biopha.2025.118388_bib46","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.cmet.2017.04.015","article-title":"Metabolic flexibility in health and disease","author":"Goodpaster","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118388_bib47","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.3390\/cimb45080420","article-title":"Oxidative stress in type 2 diabetes: impacts from pathogenesis to lifestyle modifications","author":"Caturano","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118388_bib48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fca-2018-0045","article-title":"Type-2 diabetes mellitus and cardiovascular disease","author":"Henning","year":"2018","journal-title":"Future Cardiol."},{"key":"10.1016\/j.biopha.2025.118388_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1143067","article-title":"Microvascular and macrovascular complications of type 2 diabetes mellitus: exome wide association analyses","volume":"14","author":"Mansour","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib50","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118388_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2010.06.021","article-title":"Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis c","volume":"54","author":"Garc\u00eda-Monz\u00f3n","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118388_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118388_bib54","first-page":"1277","article-title":"Hepatic stellate cells: dictating outcome in nonalcoholic fatty liver disease","author":"Wiering","year":"2023","journal-title":"CMGH"},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib55","first-page":"344","article-title":"Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology","volume":"3","author":"Weiskirchen","year":"2014","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.biopha.2025.118388_bib56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13061113","article-title":"Current guidelines for diagnosing PCOS","volume":"13","author":"Christ","year":"2023","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib58","doi-asserted-by":"crossref","first-page":"E1071","DOI":"10.1210\/clinem\/dgaa839","article-title":"Update on PCOS: consequences, challenges, and guiding treatment","volume":"106","author":"Hoeger","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2025.118388_bib59","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum. Reprod."},{"issue":"2 44-2","key":"10.1016\/j.biopha.2025.118388_bib60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1152\/ajpendo.2001.281.2.E392","article-title":"Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS)","volume":"281","author":"Dunaif","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-022-01091-0","article-title":"Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment","volume":"16","author":"Zhao","year":"2023","journal-title":"J. Ovarian Res."},{"issue":"July","key":"10.1016\/j.biopha.2025.118388_bib62","article-title":"Hyperandrogenemia and insulin resistance: the chief culprit of polycystic ovary syndrome","volume":"236","author":"Wang","year":"2019","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib63","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib64","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0889-8529(05)70074-8","article-title":"Insulin action in the normal and polycystic ovary","volume":"28","author":"Franks","year":"1999","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2025.118388_bib65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mce.2005.07.002","article-title":"Insulin regulation of GnRH gene expression through MAP kinase signaling pathways","volume":"242","author":"Kim","year":"2005","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib66","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/endo-108-4-1441","article-title":"Insulin enhancement of luteinizing hormone and Follicle-Stimulating hormone release by cultured pituitary cells","volume":"108","author":"Adashi","year":"1981","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib67","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2017-00947","article-title":"AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome","volume":"102","author":"O\u2019Reilly","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.biopha.2025.118388_bib68","first-page":"1","article-title":"Conversion of classical and 11-Oxygenated androgens by Insulin-Induced AKR1C3 in a model of human PCOS adipocytes","volume":"163","author":"Paulukinas","year":"2022","journal-title":"Endocrinology (United States)"},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib69","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cmet.2010.06.010","article-title":"Rescue of Obesity-Induced infertility in female mice due to a Pituitary-Specific knockout of the insulin receptor (IR)","volume":"12","author":"Brothers","year":"2010","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib70","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/oby.21033","article-title":"The role of androgens in metabolism, obesity and diabetes in males and females","volume":"23","author":"Navarro","year":"2015","journal-title":"Obesity (Silver Spring, Md.)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2337\/diacare.25.1.55","article-title":"Endogenous sex hormones and the development of type 2 diabetes in older men and women: the rancho bernardo study","volume":"25","author":"Oh","year":"2002","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib72","first-page":"248","article-title":"Emerging role of testosterone in pancreatic \u03b2\u2013cell function and insulin secretion","volume":"46","author":"Xu","year":"2020","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118388_bib73","article-title":"Association of androgen excess with glucose intolerance in women with polycystic ovary syndrome","volume":"2018","author":"Zhang","year":"2018","journal-title":"BioMed. Res. Int."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib74","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s00125-003-1324-0","article-title":"Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots","volume":"47","author":"Dicker","year":"2004","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib75","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1677\/joe.1.07070","article-title":"Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women","volume":"192","author":"Corbould","year":"2007","journal-title":"J. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004274","article-title":"Effect of testosterone on insulin stimulated IRS1 ser phosphorylation in primary rat myotubes - a potential model for PCOS-related insulin resistance","volume":"4","author":"Allemand","year":"2009","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.biopha.2025.118388_bib77","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100961R","article-title":"Androgen-induced insulin resistance is ameliorated by deletion of hepatic androgen receptor in females","volume":"35","author":"Andrisse","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118388_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2021.105829","article-title":"Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats","volume":"208","author":"Cui","year":"2021","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib79","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.fertnstert.2022.02.028","article-title":"Subclinical atherosclerosis and polycystic ovary syndrome","volume":"117","author":"Gomez","year":"2023","journal-title":"Fertil. Steril."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib80","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society","volume":"95","author":"Wild","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib81","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.yjmcc.2009.08.028","article-title":"Interaction of myocardial insulin receptor and IGF receptor signaling in exercise-induced cardiac hypertrophy","volume":"47","author":"Ikeda","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2025.118388_bib82","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10557-020-07071-0","article-title":"Inflammatory cytokines and chemokines as therapeutic targets in heart failure","volume":"34","author":"Hanna","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.biopha.2025.118388_bib83","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231164548","article-title":"Insulin resistance and cardiovascular disease","author":"Kosmas","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.biopha.2025.118388_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2023.12.018","article-title":"Prevention of cardiorenal complications in people with type 2 diabetes and obesity","author":"Drucker","year":"2024","journal-title":"Cell Metabolism 116"},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib85","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2009.1060","article-title":"Diet and lifestyle risk factors associated with incident hypertension in women","volume":"302","author":"Forman","year":"2009","journal-title":"JAMA"},{"issue":"9294","key":"10.1016\/j.biopha.2025.118388_bib86","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/S0140-6736(01)06710-1","article-title":"Assessment of frequency of progression to hypertension in non-hypertensive participants in the framingham heart study: a cohort study","volume":"358","author":"Vasan","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib87","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0091-7435(87)90087-9","article-title":"Incidence and precursors of hypertension in young adults: the framingham offspring study","volume":"16","author":"Garrison","year":"1987","journal-title":"Prev. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib88","doi-asserted-by":"crossref","first-page":"80","DOI":"10.21037\/gs.2019.12.03","article-title":"Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery","volume":"9","author":"Shariq","year":"2020","journal-title":"Gland Surg."},{"key":"10.1016\/j.biopha.2025.118388_bib89","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijcard.2016.12.083","article-title":"Glucose transporters in healthy heart and in cardiac disease","author":"Szablewski","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib90","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1097-2765(05)00015-8","article-title":"Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction","volume":"6","author":"Michael","year":"2000","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib91","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/db08-1607","article-title":"Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men","volume":"58","author":"St\u01ce\u00e1cakov\u00e1","year":"2009","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib92","article-title":"Pathophysiologic contributions of visceral adiposity to left ventricular diastolic dysfunction","volume":"10","author":"Nagata","year":"2023","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"7","key":"10.1016\/j.biopha.2025.118388_bib93","article-title":"The role of epicardial adipose tissue in the development of atrial fibrillation, coronary artery disease and chronic heart failure in the context of obesity and type 2 diabetes mellitus: a narrative review","volume":"9","author":"Krishnan","year":"2022","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib94","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/sj.ijo.0802858","article-title":"Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases","volume":"28","author":"Montani","year":"2004","journal-title":"Int. J. Obes."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib95","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.bbalip.2009.09.023","article-title":"Lipotoxicity in the heart","volume":"1801","author":"Wende","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib96","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1152\/physrev.00034.2018","article-title":"Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue","volume":"99","author":"Saxton","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2025.118388_bib97","doi-asserted-by":"crossref","DOI":"10.1177\/1179551418792257","article-title":"The impact of insulin resistance and chronic kidney disease on inflammation and cardiovascular disease","author":"Kosmas","year":"2018","journal-title":"Clin. Med. Insights Endocrinol. Diab."},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib98","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/01.HYP.19.6.621","article-title":"Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans","volume":"19","author":"Anderson","year":"1992","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib99","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/HYPERTENSIONAHA.110.160671","article-title":"Sympathetic response to insulin is mediated by melanocortin 3\/4 receptors in the hypothalamic paraventricular nucleus","volume":"57","author":"Ward","year":"2011","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11154-012-9229-1","article-title":"Role of insulin resistance in endothelial dysfunction","volume":"14","author":"Muniyappa","year":"2013","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.biopha.2025.118388_bib101","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.freeradbiomed.2014.05.016","article-title":"Regulation of obesity and insulin resistance by nitric oxide","volume":"73","author":"Sansbury","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib102","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1097\/01.hjh.0000239300.48130.07","article-title":"Abnormalities of renal sodium handling in the metabolic syndrome. Results of the olivetti heart study","volume":"24","author":"Strazzullo","year":"2006","journal-title":"J. Hypertens."},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib103","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","article-title":"Relationship between physical activity, body mass index, and risk of heart failure","volume":"69","author":"Cronin","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.003921","article-title":"Obesity and subtypes of incident cardiovascular disease","volume":"5","author":"Ndumele","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib106","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved ejection fraction and diabetes: JACC State-of-the-Art review","volume":"73","author":"McHugh","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib107","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijcard.2015.04.110","article-title":"Inflammation in HFpEF: key or circumstantial?","volume":"189","author":"Van Empel","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"82","key":"10.1016\/j.biopha.2025.118388_bib108","first-page":"201","article-title":"Heart failure with preserved ejection Fraction\u2014a concise review","volume":"22","author":"Adamczak","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib109","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: european consensus on definition and diagnosis","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib111","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/JOE-15-0533","article-title":"Insulin resistance and sarcopenia: mechanistic links between common co-morbidities","volume":"229","author":"Cleasby","year":"2016","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118388_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1185221","article-title":"Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management","author":"Wei","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib113","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/oby.21356","article-title":"Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity","volume":"24","author":"Ma","year":"2016","journal-title":"Obes. (Silver Spring Md. )"},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib114","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00223-016-0123-9","article-title":"Associations of sarcopenic obesity and dynapenic obesity with bone mineral density and incident fractures over 5-10 years in Community-Dwelling older adults","volume":"99","author":"Scott","year":"2016","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12877-019-1195-y","article-title":"Association of sarcopenic obesity with the risk of all-cause mortality among adults over a broad range of different settings: a updated meta-analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.biopha.2025.118388_bib116","first-page":"1","article-title":"A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors","author":"Izzo","year":"2021","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib117","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3945\/ajcn.2009.28047","article-title":"Longitudinal study of muscle strength, quality, and adipose tissue infiltration","volume":"90","author":"Delmonico","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib118","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1152\/jappl.2000.89.1.104","article-title":"Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content","volume":"89","author":"Goodpaster","year":"2000","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.biopha.2025.118388_bib119","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s13679-023-00520-5","article-title":"Obesity, metabolic syndrome, and osteoarthritis\u2014an updated review","author":"Sampath","year":"2023","journal-title":"Curr. Obes. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib120","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.rdc.2008.05.004","article-title":"The symptoms of osteoarthritis and the genesis of pain","volume":"34","author":"Hunter","year":"2008","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib121","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/jama.2020.22171","article-title":"Diagnosis and treatment of hip and knee osteoarthritis: a review","volume":"325","author":"Katz","year":"2021","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib122","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc12-0924","article-title":"Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study","volume":"36","author":"Schett","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib123","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00296-017-3676-7","article-title":"Effects of medication-treated diabetes on incidence and progression of knee osteoarthritis: a longitudinal analysis of the osteoarthritis initiative data","volume":"37","author":"Shirinsky","year":"2017","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib124","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/acr.24173","article-title":"Impact of diabetes mellitus on knee osteoarthritis pain and physical and mental status: data from the osteoarthritis initiative","volume":"73","author":"Eitner","year":"2021","journal-title":"Arthritis Care Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib125","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1152\/ajpendo.00070.2021","article-title":"Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity","volume":"321","author":"Kunz","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib126","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/art.39561","article-title":"Suppressive effects of insulin on tumor necrosis factor-dependent early osteoarthritic changes associated with obesity and type 2 diabetes mellitus","volume":"68","author":"Hamada","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.biopha.2025.118388_bib127","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diabres.2016.10.021","article-title":"Osteoarthritis and type 2 diabetes mellitus: what are the links?","author":"Courties","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2019.01.005","article-title":"Type 2 diabetes mellitus and osteoarthritis","volume":"49","author":"Veronese","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib129","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.joca.2015.04.026","article-title":"Characterization of diabetic osteoarthritic cartilage and role of high glucose environment on chondrocyte activation: toward pathophysiological delineation of diabetes mellitus-related osteoarthritis","volume":"23","author":"Laiguillon","year":"2015","journal-title":"Osteoarthr. Cartil."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib130","doi-asserted-by":"crossref","DOI":"10.1186\/ar2713","article-title":"Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in chondrocytes from osteoarthritic versus normal human cartilage","volume":"11","author":"Rosa","year":"2009","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib131","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P","article-title":"Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis","volume":"46","author":"Verzijl","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib132","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1226-z","article-title":"Sex differences in the association of skin advanced glycation endproducts with knee osteoarthritis progression","volume":"19","author":"Eaton","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib133","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1210\/clinem\/dgad415","article-title":"Obesity and skeletal fragility","volume":"109","author":"Chen","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib134","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2025.118388_bib135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2213-8587(15)00283-1","article-title":"Type 2 diabetes and the skeleton: new insights into sweet bones","author":"Shanbhogue","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118388_bib136","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.tem.2022.02.006","article-title":"Assessment and treatment of osteoporosis and fractures in type 2 diabetes","author":"Sheu","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.biopha.2025.118388_bib137","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00198-014-2704-7","article-title":"Bone quality assessment in type 2 diabetes mellitus","volume":"25","author":"Dhaliwal","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib138","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib139","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1210\/edrv.23.1.0456","article-title":"Changes in proinflammatory cytokine activity after menopause","volume":"23","author":"Pfeilschifter","year":"2002","journal-title":"Endocr. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib140","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1074\/jbc.271.9.4605","article-title":"Interleukin-1\u03b1 activates an NF-\u03baB-like factor in osteoclast-like cells","volume":"271","author":"Jimi","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118388_bib141","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MED.0000000000000733","article-title":"Effects of diabetes on osteocytes","author":"Kaur","year":"2022","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib142","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135236","article-title":"Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes","volume":"5","author":"Eckhardt","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2025.118388_bib143","article-title":"Bone canonical wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength","volume":"12","author":"Leanza","year":"2023","journal-title":"ELife"},{"issue":"7","key":"10.1016\/j.biopha.2025.118388_bib144","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jbmr.5650110709","article-title":"Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia","volume":"11","author":"Katayama","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11914-017-0341-8","article-title":"Is diabetic skeletal fragility associated with microvascular complications in bone?","volume":"15","author":"Fajardo","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"issue":"10284","key":"10.1016\/j.biopha.2025.118388_bib146","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2025.118388_bib147","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2337\/db16-1444","article-title":"Metabolic syndrome, insulin resistance, and cognitive dysfunction: does your metabolic profile affect your brain?","volume":"66","author":"Neergaard","year":"2017","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib148","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/oby.22243","article-title":"Inward glucose transfer accounts for Insulin-Dependent increase in brain glucose metabolism associated with Diet-Induced obesity","volume":"26","author":"Bahri","year":"2018","journal-title":"Obesity"},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib149","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2337\/db10-0940","article-title":"Effects of insulin on brain glucose metabolism in impaired glucose tolerance","volume":"60","author":"Hirvonen","year":"2011","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib150","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.2337\/db12-1460","article-title":"Weight loss after bariatric surgery reverses insulin-induced increases in brain glucose metabolism of the morbidly obese","volume":"62","author":"Tuulari","year":"2013","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib151","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/0006-291X(84)90903-3","article-title":"Stimulation of synaptosomal uptake of neurotransmitter amino acids by insulin: possible role of insulin as a neuromodulator","volume":"119","author":"Rhoads","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib152","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0006-8993(03)02679-9","article-title":"Insulin affects synaptosomal GABA and glutamate transport under oxidative stress conditions","volume":"977","author":"Duarte","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2025.118388_bib153","article-title":"Insulin inhibits specific norepinephrine uptake in neuronal cultures from rat brain","volume":"398","author":"Boyd","year":"1986"},{"issue":"May","key":"10.1016\/j.biopha.2025.118388_bib154","first-page":"1","article-title":"Significance of brain glucose hypometabolism, altered insulin signal transduction, and insulin resistance in several neurological diseases","volume":"13","author":"Bl\u00e1zquez","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118388_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2014.00161","article-title":"Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and alzheimer\u2019s disease","author":"Bl\u00e1zquez","year":"2014","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib156","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.61.5.661","article-title":"Diabetes mellitus and risk of alzheimer disease and decline in cognitive function","volume":"61","author":"Arvanitakis","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.biopha.2025.118388_bib157","unstructured":"Yaffe, K., Kanaya, A., Lindquist, K., Simonsick, E.M., Harris, T., Shorr, R.I., et al., n.d. The Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline."},{"key":"10.1016\/j.biopha.2025.118388_bib158","first-page":"119","article-title":"Adiposity, hyperinsulinemia, diabetes and Alzheimer\u2019s disease","author":"Luchsinger","year":"2008","journal-title":"Epidemiol. Perspect. Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118388_bib159","article-title":"Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels","volume":"11","author":"Carantoni","year":"2000"},{"key":"10.1016\/j.biopha.2025.118388_bib160","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.neuropharm.2010.04.005","article-title":"Oxidative stress in Alzheimer disease: a possibility for prevention","author":"Bonda","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118388_bib161","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","author":"Kinney","year":"2018","journal-title":"Alzheimer\u2019S. Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.biopha.2025.118388_bib162","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12017-011-8155-9","article-title":"Oxidative stress and \u03b2-amyloid protein in Alzheimer\u2019s disease","author":"Cai","year":"2011","journal-title":"NeuroMolecular Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib163","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.nbd.2010.04.011","article-title":"Preclinical alzheimer disease: brain oxidative stress, A\u03b2 peptide and proteomics","volume":"39","author":"Aluise","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118388_bib164","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm0902-936","article-title":"Inflammation takes on alzheimer disease","volume":"8","author":"Golde","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118388_bib165","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in parkinson disease","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2025.118388_bib166","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bmb\/ldn013","article-title":"A review of Parkinson\u2019s disease","author":"Davie","year":"2008","journal-title":"Br. Med. Bull."},{"issue":"16","key":"10.1016\/j.biopha.2025.118388_bib167","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.3390\/nu15163585","article-title":"The molecular mechanisms of the relationship between insulin resistance and Parkinson\u2019s disease pathogenesis","volume":"15","author":"Ruiz-Pozo","year":"2023","journal-title":"Nutrients"},{"issue":"19","key":"10.1016\/j.biopha.2025.118388_bib168","doi-asserted-by":"crossref","first-page":"E1654","DOI":"10.1212\/WNL.0000000000005475","article-title":"Diabetes mellitus and parkinson disease","volume":"90","author":"Pagano","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib169","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","article-title":"Association between diabetes and subsequent parkinson disease: a record-linkage cohort study","volume":"91","author":"De Pablo-Fernandez","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib170","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030740","article-title":"Insulin resistance promotes Parkinson\u2019s disease through aberrant expression of \u03b1-synuclein, mitochondrial dysfunction, and deregulation of the Polo-Like kinase 2 signaling","volume":"9","author":"Hong","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118388_bib171","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2025.118388_bib172","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2025.118388_bib173","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"6645","key":"10.1016\/j.biopha.2025.118388_bib174","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118388_bib175","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2024","journal-title":"Int. J. Obes."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib176","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.metabol.2014.10.018","article-title":"Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis","volume":"64","author":"Chen","year":"2015","journal-title":"Metab. Clin. Exp."},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib177","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2017.31","article-title":"Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history","volume":"7","author":"Clamp","year":"2017","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.biopha.2025.118388_bib178","doi-asserted-by":"crossref","unstructured":"Goodpaster, B.H., Kelley, D.E., Wing, R.R., Meier, A., Thaete, F.L., 1999. Effects of Weight Loss on Regional Fat Distribution and Insulin Sensitivity in Obesity. vol. 48.","DOI":"10.2337\/diabetes.48.4.839"},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib179","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/oby.23371","article-title":"Benefits of weight loss of 10% or more in patients with overweight or obesity: a review","volume":"30","author":"Tahrani","year":"2022","journal-title":"Obesity"},{"issue":"10120","key":"10.1016\/j.biopha.2025.118388_bib180","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet"},{"issue":"10322","key":"10.1016\/j.biopha.2025.118388_bib181","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib182","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2337\/dc15-1407","article-title":"Weight change-adjusted effects of gastric bypass surgery on glucose metabolism: 2- and 10-year results from the Swedish obese subjects (SOS) study","volume":"39","author":"Sj\u00f6holm","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.118388_bib183","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","author":"Ryan","year":"2017","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.biopha.2025.118388_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(24)00346-2","article-title":"Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials","author":"Kanbour","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118388_bib185","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2337\/dc16-1728","article-title":"Physical activity\/exercise and diabetes: a position statement of the American diabetes association","author":"Colberg","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.118388_bib186","doi-asserted-by":"crossref","DOI":"10.1186\/s40798-019-0194-z","article-title":"The role of aerobic training variables progression on glycemic control of patients with type 2 diabetes: a systematic review with meta-analysis","author":"Delevatti","year":"2019","journal-title":"Sports Med. Open"},{"key":"10.1016\/j.biopha.2025.118388_bib187","doi-asserted-by":"crossref","first-page":"12385","DOI":"10.1002\/jcp.28066","article-title":"Molecular mechanisms by which aerobic exercise induces insulin sensitivity","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"943","key":"10.1016\/j.biopha.2025.118388_bib188","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/pgmj.2003.010553","article-title":"Barriers to physical activity in patients with diabetes","volume":"80","author":"Thomas","year":"2004","journal-title":"Postgrad. Med. J."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib189","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/2249-4863.219998","article-title":"Exercise in patients with type 2 diabetes: facilitators and barriers - a qualitative study","volume":"6","author":"Advika","year":"2017","journal-title":"J. Fam. Med. Prim. Care"},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib190","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib191","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/1573399816666200705210006","article-title":"Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus","volume":"17","author":"Ida","year":"2021","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.biopha.2025.118388_bib192","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: insights from clinical trials","author":"Bikou","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib193","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"10077","key":"10.1016\/j.biopha.2025.118388_bib194","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, Double-Blind trial","volume":"389","author":"Le Roux","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118388_bib195","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","author":"Aronne","year":"2023","journal-title":"Jama 10065"},{"key":"10.1016\/j.biopha.2025.118388_bib196","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031264","article-title":"Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-Mediated glucose transport","author":"Herman","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118388_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/S1262-3636(03)72785-2","article-title":"Reducing insulin resistance with metformin: the evidence today","author":"Giannarelli","year":"2003","journal-title":"Diabetes Metab."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib198","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1677\/JME-08-0130","article-title":"Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes","volume":"42","author":"Zhang","year":"2009","journal-title":"J. Mol. Endocrinol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118388_bib199","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by which metformin reduces glucose production in type 2 diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2025.118388_bib200","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.44493","article-title":"Role of metformin in polycystic ovary syndrome (PCOS): related infertility","author":"Attia","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib201","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijgo.2015.06.063","article-title":"A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome","volume":"132","author":"El-Khayat","year":"2016","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib202","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ebmental-2021-300291","article-title":"Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology","volume":"25","author":"Fitzgerald","year":"2022","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.biopha.2025.118388_bib203","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.933570","article-title":"The role of metformin in treatment of weight gain associated with atypical antipsychotic treatment in children and adolescents: a systematic review and meta-analysis of randomized controlled trials","author":"Mansuri","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"21","key":"10.1016\/j.biopha.2025.118388_bib204","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.biopha.2025.118388_bib205","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib206","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/phar.1303","article-title":"The clinical efficacy and safety of sodium glucose Cotransporter-2 inhibitors in adults with type 2 diabetes mellitus","volume":"33","author":"Riser Taylor","year":"2013","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib207","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2017-01838","article-title":"Empagliflozin treatment is associated with improved \u03b2 -Cell function in type 2 diabetes mellitus","volume":"103","author":"Al Jobori","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib208","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2025.118388_bib209","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","author":"Lee","year":"2018","journal-title":"Obes. Rev."},{"key":"10.1016\/j.biopha.2025.118388_bib210","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib211","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14740338.2019.1626823","article-title":"An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors","volume":"18","author":"Lamos","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"12","key":"10.1016\/j.biopha.2025.118388_bib212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the forgotten diabetes medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.biopha.2025.118388_bib213","doi-asserted-by":"crossref","unstructured":"Lehmanns, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willsonll, T.M., Kliewer-T], S.A., 1995. Communication An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor y (PPARy)*.","DOI":"10.1074\/jbc.270.22.12953"},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib214","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.biopha.2025.118388_bib215","doi-asserted-by":"crossref","unstructured":"Sugii, S., Olson, P., Sears, D.D., Saberi, M., Atkins, A.R., Barish, G.D., et al., 2009. PPAR activation in adipocytes is sufficient for systemic insulin sensitization.","DOI":"10.1073\/pnas.0912487106"},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib216","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3892\/mmr.2013.1714","article-title":"Role of PPARs in inflammatory processes associated with metabolic syndrome (Review)","author":"Fuentes","year":"2013","journal-title":"Mol. Med. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib217","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.biopha.2025.118388_bib218","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1152\/ajpendo.00522.2004","article-title":"Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue","volume":"288","author":"Rasouli","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2025.118388_bib219","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/jc.2003-030723","article-title":"Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal Proliferator-Activated receptor agonists provide a rational therapeutic approach","author":"Bays","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib220","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jpen.2481","article-title":"Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review","volume":"47","author":"McClelland","year":"2023","journal-title":"J. Parenter. Enter. Nutr."},{"issue":"10","key":"10.1016\/j.biopha.2025.118388_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30909","article-title":"Effects of antidiabetic agents on platelet characteristics with implications in Alzheimer\u2019s disease: mendelian randomization and colocalization study","volume":"10","author":"Xie","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib222","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-41854-2","article-title":"Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: a systematic review and Meta-Analysis of randomised controlled trials","volume":"9","author":"Alam","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118388_bib223","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ejmech.2016.12.020","article-title":"Thiazolidinediones and PPAR orchestra as antidiabetic agents: from past to present","volume":"126","author":"Yasmin","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib224","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","article-title":"Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes","volume":"97","author":"Horowitz","year":"2012","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib225","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib226","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib227","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1210\/jc.2014-2291","article-title":"Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study","volume":"100","author":"Rizzo","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib228","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","article-title":"The glucagon-like peptide 1 analog liraglutide reduces TNF-\u03b1-induced oxidative stress and inflammation in endothelial cells","volume":"221","author":"Shiraki","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2025.118388_bib229","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","author":"Masson","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib230","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib231","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.metabol.2014.05.008","article-title":"Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells","volume":"63","author":"Li","year":"2014","journal-title":"Metab. Clin. Exp."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib232","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-0985-7","article-title":"The GLP-1 receptor agonists exenatide and liraglutide activate glucose transport by an AMPK-dependent mechanism","volume":"14","author":"Andreozzi","year":"2016","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.biopha.2025.118388_bib233","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10148","key":"10.1016\/j.biopha.2025.118388_bib234","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(18)31826-9","article-title":"Semaglutide and GLP-1 analogues as weight-loss agents","volume":"392","author":"Kluger","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118388_bib235","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","author":"Garvey","year":"2022","journal-title":"Nat. Med. 25"},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib236","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int. J. Obes."},{"issue":"18","key":"10.1016\/j.biopha.2025.118388_bib237","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib238","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/2040622315620180","article-title":"The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity","volume":"7","author":"Crane","year":"2016","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.biopha.2025.118388_bib239","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13300-015-0127-x","article-title":"Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists","author":"Uccellatore","year":"2015","journal-title":"Diabetes Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib241","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1\u20137 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib242","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib243","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2018-02685","article-title":"Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide","volume":"104","author":"Fonseca","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"October","key":"10.1016\/j.biopha.2025.118388_bib244","first-page":"2","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"issue":"10454","key":"10.1016\/j.biopha.2025.118388_bib245","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118388_bib246","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med. 112"},{"issue":"19","key":"10.1016\/j.biopha.2025.118388_bib247","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.biopha.2025.118388_bib248","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-Weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib249","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib250","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2025.118388_bib251","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118388_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in Male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2025.118388_bib253","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and","author":"Chuong","year":"2023","journal-title":"Modul. Cent. GABA Neurotransmission"},{"key":"10.1016\/j.biopha.2025.118388_bib254","article-title":"DA5-CH and semaglutide protect against neurodegeneration and reduce \u03b1 -Synuclein levels in the 6-OHDA Parkinson\u2019s disease rat model","volume":"2022","author":"Zhang","year":"2022","journal-title":"Park. \u2019S. Dis."},{"key":"10.1016\/j.biopha.2025.118388_bib255","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US","author":"Wang","year":"2024","journal-title":"Alzheimer\u2019S. Dement."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib256","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther."},{"issue":"ember","key":"10.1016\/j.biopha.2025.118388_bib257","first-page":"5","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib258","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib259","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118388_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113499","article-title":"Tirzepatide\u2019s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance","volume":"143","author":"Xia","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"August","key":"10.1016\/j.biopha.2025.118388_bib261","first-page":"1","article-title":"Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats","volume":"14","author":"Guo","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118388_bib262","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113877","article-title":"GLP-1\/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K\/AKT mediated suppression of oxidative stress","volume":"146","author":"Tian","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2025.118388_bib263","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molmet.2013.04.001","article-title":"Adiponectin, driver or passenger on the road to insulin sensitivity?","author":"Ye","year":"2013","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib264","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves Beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2025.118388_bib265","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib266","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic Dysfunction\u2013Associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.biopha.2025.118388_bib267","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib268","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118388_bib269","series-title":"Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity","article-title":"Viking Therapeutics Press release","year":"2025"},{"key":"10.1016\/j.biopha.2025.118388_bib270","series-title":"Roche reports positive Phase Ib results for its dual GLP-1\/GIP receptor agonist CT-388 in people with obesity","article-title":"Roche press release","year":"2024"},{"issue":"12","key":"10.1016\/j.biopha.2025.118388_bib271","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrendo.2010.187","article-title":"The metabolic actions of glucagon revisited","volume":"6","author":"Habegger","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib272","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13372","article-title":"The incretin\/glucagon system as a target for pharmacotherapy of obesity","volume":"23","author":"Del Prato","year":"2022","journal-title":"Obes. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib273","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib274","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1124\/jpet.122.001440","article-title":"The effects of dual GLP-1\/Glucagon receptor agonists with different receptor selectivity in mouse models of obesity and nonalcoholic steatohepatitis","volume":"384","author":"Kayed","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118388_bib275","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/S0168-8278(20)31395-7","article-title":"GLP-1\/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model","volume":"73","author":"Nestor","year":"2020","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118388_bib276","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.biopha.2025.118388_bib277","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2025.118388_bib278","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13212","article-title":"Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: a comparative study between mice and non-human primates","author":"Elvert","year":"2018","journal-title":"Diabetes Obesity Metabolism (May 2017) 116"},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib279","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118388_bib280","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib281","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"July","key":"10.1016\/j.biopha.2025.118388_bib282","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib283","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/dom.14035","article-title":"Incretin combination therapy for the treatment of non-alcoholic steatohepatitis","volume":"22","author":"Kannt","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib284","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013Hormone-Receptor agonist retatrutide for obesity \u2014 a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib285","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/dom.12585","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib286","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/oby.2012.67","article-title":"The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin","volume":"20","author":"Kosinski","year":"2012","journal-title":"Obesity"},{"issue":"ement_1","key":"10.1016\/j.biopha.2025.118388_bib287","article-title":"Evaluating the Sub-chronic effects of MEDI0382, a GLP-1\/Glucagon receptor dual agonist, on weight loss in Male Ob\/Ob mice","volume":"67","author":"Oldham","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2025.118388_bib288","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/DDDT.S3225","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes","volume":"2","author":"Ryan","year":"2008","journal-title":"Drug Des. Dev. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib289","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus","volume":"34","author":"Fineman","year":"2002","journal-title":"Horm. Metab. Res."},{"issue":"14","key":"10.1016\/j.biopha.2025.118388_bib290","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2025.118388_bib291","article-title":"Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases","author":"Sonne","year":"2020","journal-title":"Mol. Metab. Prepr."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib292","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/jpet.119.263392","article-title":"The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy","volume":"374","author":"Larsen","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118388_bib293","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114969","article-title":"Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss","volume":"164","author":"Larsen","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2025.118388_bib294","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/jpet.119.257576","article-title":"The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy","volume":"370","author":"Larsen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib295","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.14283\/jpad.2024.74","article-title":"The insulin sensitizer KBP-336 prevents diabetes-induced cognitive decline in ZDF rats","volume":"11","author":"Larsen","year":"2024","journal-title":"J. Prev. Alzheimer\u2019S. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib296","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03361-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection \u2013 a novel disease-modifying osteoarthritis drug","volume":"26","author":"Mohamed","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biopha.2025.118388_bib297","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter? \u2013 Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.biopha.2025.118388_bib298","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/bph.16329","article-title":"Are insulin sensitizers the new strategy to treat type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight","volume":"181","author":"Melander","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"June","key":"10.1016\/j.biopha.2025.118388_bib299","article-title":"KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats","volume":"53","author":"Andreassen","year":"2021","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib300","doi-asserted-by":"crossref","first-page":"E145","DOI":"10.1152\/ajpendo.00092.2024","article-title":"The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes","volume":"327","author":"Larsen","year":"2024","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.biopha.2025.118388_bib301","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"175397","key":"10.1016\/j.biopha.2025.118388_bib302","first-page":"1","article-title":"Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin","volume":"938","author":"Melander","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118388_bib303","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, dose-finding phase 2 trial","author":"Lau","year":"2021","journal-title":"Lancet 6736(21"},{"key":"10.1016\/j.biopha.2025.118388_bib304","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejphar.2015.05.051","article-title":"KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration","volume":"762","author":"Hjuler","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118388_bib305","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/GME.0b013e31827c58ab","article-title":"Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats","volume":"20","author":"Feigh","year":"2013","journal-title":"Menopause"},{"issue":"23","key":"10.1016\/j.biopha.2025.118388_bib306","first-page":"1","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"6736","author":"Frias","year":"2023","journal-title":"Lancet (Lond. Engl.)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib307","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/jpet.119.263392","article-title":"The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy","volume":"374","author":"Larsen","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib308","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.117.241281","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 works as adjunct to metformin on fasting hyperglycemia and HbA1c in a rat model of type 2 diabetes","volume":"362","author":"Hjuler","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118388_bib309","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1517\/14712598.2010.526104","article-title":"Oral salmon calcitonin pharmacology in osteoporosis","author":"Henriksen","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib310","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1819-9","article-title":"Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model","volume":"21","author":"Katri","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib311","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03361-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection \u2013 a novel disease-modifying osteoarthritis drug","volume":"26","author":"Mohamed","year":"2024","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib312","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/jpet.121.000567","article-title":"AM833 is a novel agonist of calcitonin family g protein\u2013coupled receptors: pharmacological comparison with six selective and nonselective agonists","volume":"377","author":"Fletcher","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10286","key":"10.1016\/j.biopha.2025.118388_bib313","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118388_bib314","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013Semaglutide in adults with overweight or obesity and type 2 diabetes","author":"Davies","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118388_bib315","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","author":"Garvey","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"ement_1","key":"10.1016\/j.biopha.2025.118388_bib316","article-title":"763-P: CagriSema improves insulin sensitivity in Diet-Induced obese rats","volume":"73","author":"Secher","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2025.118388_bib317","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118388_bib318","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118388_bib319","first-page":"372","article-title":"Potent anti-obesity effects of amylin analogue ZP8396 in combination with semaglutide in DIO rats","author":"Skarbaliene","year":"2021","journal-title":"Obes. Soc. Annu. Meet."},{"issue":"Supplement_1","key":"10.1016\/j.biopha.2025.118388_bib320","doi-asserted-by":"crossref","DOI":"10.2337\/db24-1668-P","article-title":"1668-P: novel Once-Weekly amylin analog petrelintide (ZP8396) is well tolerated with improved GI tolerability after multiple dosing","volume":"73","author":"Griffin","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2025.118388_bib321","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175397","article-title":"Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin","volume":"938","author":"Melander","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib322","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-020-00678-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","volume":"21","author":"Larsen","year":"2021","journal-title":"BMC Endocr. Disord."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib323","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00275.2010","article-title":"Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates","volume":"299","author":"Bello","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118388_bib324","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s13300-020-00926-7","article-title":"Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes","volume":"11","author":"Matthews","year":"2020","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2025.118388_bib325","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1095753","article-title":"Effect of dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity","author":"Zaffina","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118388_bib326","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"June","key":"10.1016\/j.biopha.2025.118388_bib327","article-title":"Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss","volume":"954","author":"Larsen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118388_bib328","author":"Novo Nordisk","year":"2025","journal-title":"Novo Nordisk successfully completes phase 1b\/2a trial with subcutaneous amycretin in people with overweight or obesity"},{"key":"10.1016\/j.biopha.2025.118388_bib329","author":"Novo Nordisk","year":"2024","journal-title":"CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial"},{"issue":"10120","key":"10.1016\/j.biopha.2025.118388_bib330","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib331","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib332","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118388_bib333","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/jcsm.12783","article-title":"Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis","author":"Petermann-Rocha","year":"2022","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"8","key":"10.1016\/j.biopha.2025.118388_bib334","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11916-013-0356-5","article-title":"Worldwide epidemiology of fibromyalgia","volume":"17","author":"Queiroz","year":"2013","journal-title":"Curr. Pain. Headache Rep."},{"key":"10.1016\/j.biopha.2025.118388_bib335","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib336","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer\u2019s disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib337","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/pedi.12473","article-title":"Metformin; a review of its history and future: from lilac to longevity","volume":"18","author":"Thomas","year":"2017","journal-title":"Pediatr. Diabetes"},{"issue":"9","key":"10.1016\/j.biopha.2025.118388_bib338","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2025.118388_bib339","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/394623","article-title":"Effects of metformin on the regulation of free fatty acids in insulin resistance: a double-blind, placebo-controlled study","volume":"2012","author":"Castro Cabezas","year":"2012","journal-title":"J. Nutr. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib340","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/vhrm.2006.2.3.203","article-title":"Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes","volume":"2","author":"Pullman","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"issue":"22","key":"10.1016\/j.biopha.2025.118388_bib341","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2025.118388_bib342","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapyin type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.biopha.2025.118388_bib343","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118388_bib344","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118388_bib345","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib346","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118388_bib347","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"issue":"9683","key":"10.1016\/j.biopha.2025.118388_bib348","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"9951","key":"10.1016\/j.biopha.2025.118388_bib349","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.biopha.2025.118388_bib350","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118388_bib351","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-023-01797-5","article-title":"Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","volume":"22","author":"Lingvay","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2025.118388_bib352","first-page":"96","article-title":"Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program","author":"le Roux","year":"2022","journal-title":"Obesity (August 2022)"},{"key":"10.1016\/j.biopha.2025.118388_bib353","article-title":"Efficacy and safety of tirzepatide in adults with type 1 diabetes: a proof of concept observational study","author":"Akturk","year":"2024","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.biopha.2025.118388_bib354","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1309118","article-title":"Efficacy and safety of mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials","author":"Nalisa","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"ement_1","key":"10.1016\/j.biopha.2025.118388_bib355","article-title":"262-OR: pemvidutide, a GLP-1\/Glucagon dual receptor agonist, in subjects with overweight or obesity\u2014A 48-Week, Placebo-Controlled, phase 2 (MOMENTUM) trial","volume":"73","author":"Aronne","year":"2024","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.biopha.2025.118388_bib356","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118388_bib357","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","author":"Rosenstock","year":"2023","journal-title":"Lancet 116"},{"issue":"7","key":"10.1016\/j.biopha.2025.118388_bib358","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118388_bib359","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MED.0000000000000716","article-title":"Long-acting amylin analogues for the management of obesity","volume":"29","author":"Mathiesen","year":"2022","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:26:07Z","timestamp":1772789167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225005827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":359,"alternative-id":["S0753332225005827"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118388","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the root cause of obesity-related comorbidities through weight independent and dependent actions on insulin sensitivity: Benefits of dual amylin and calcitonin receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118388"}}